PortalPublikationenGerman guideline for diagnosis and treatment of multiple scl...

German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise

Standard

German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise. / Heesen, C; Mokry, C; Salmen, A; Hegen, H; Mäurer, M; Warnke, C; Gehring, K; Berthele, A; Meier, U.

in: MULT SCLER RELAT DIS, Jahrgang 63, 103828, 07.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Letter › Forschung

Harvard

Heesen, C, Mokry, C, Salmen, A, Hegen, H, Mäurer, M, Warnke, C, Gehring, K, Berthele, A & Meier, U 2022, 'German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise', MULT SCLER RELAT DIS, Jg. 63, 103828. https://doi.org/10.1016/j.msard.2022.103828

APA

Heesen, C., Mokry, C., Salmen, A., Hegen, H., Mäurer, M., Warnke, C., Gehring, K., Berthele, A., & Meier, U. (2022). German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise. MULT SCLER RELAT DIS, 63, [103828]. https://doi.org/10.1016/j.msard.2022.103828

Vancouver

Heesen C, Mokry C, Salmen A, Hegen H, Mäurer M, Warnke C et al. German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise. MULT SCLER RELAT DIS. 2022 Jul;63. 103828. https://doi.org/10.1016/j.msard.2022.103828

Bibtex

@article{a6d35265cf8f420f995ddbc5867c1fe7,
title = "German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise",
abstract = "We performed a web-based survey among German-speaking neurologists to evaluate the acceptance of the 2021 German guideline in the diagnosis and treatment of multiple sclerosis. Based on 327 replies in total, the current survey largely reproduced the findings of an earlier, smaller survey on the prefinal consultation version of the guideline and confirmed high acceptance rates. Half of the participants were practising neurologists. Neurologists from MS centers with more than 500 patients per year (n=26) were more critical of the guideline. They reiterated some of the criticisms of the previous feedback, and, in particular, felt that safety aspects are overemphasized in the guideline, thereby superseding early aggressive therapy.",
author = "C Heesen and C Mokry and A Salmen and H Hegen and M M{\"a}urer and C Warnke and K Gehring and A Berthele and U Meier",
note = "Copyright {\textcopyright} 2022. Published by Elsevier B.V.",
year = "2022",
month = jul,
doi = "10.1016/j.msard.2022.103828",
language = "English",
volume = "63",
journal = "MULT SCLER RELAT DIS",
issn = "2211-0348",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise

AU - Heesen, C

AU - Mokry, C

AU - Salmen, A

AU - Hegen, H

AU - Mäurer, M

AU - Warnke, C

AU - Gehring, K

AU - Berthele, A

AU - Meier, U

N1 - Copyright © 2022. Published by Elsevier B.V.

PY - 2022/7

Y1 - 2022/7

N2 - We performed a web-based survey among German-speaking neurologists to evaluate the acceptance of the 2021 German guideline in the diagnosis and treatment of multiple sclerosis. Based on 327 replies in total, the current survey largely reproduced the findings of an earlier, smaller survey on the prefinal consultation version of the guideline and confirmed high acceptance rates. Half of the participants were practising neurologists. Neurologists from MS centers with more than 500 patients per year (n=26) were more critical of the guideline. They reiterated some of the criticisms of the previous feedback, and, in particular, felt that safety aspects are overemphasized in the guideline, thereby superseding early aggressive therapy.

AB - We performed a web-based survey among German-speaking neurologists to evaluate the acceptance of the 2021 German guideline in the diagnosis and treatment of multiple sclerosis. Based on 327 replies in total, the current survey largely reproduced the findings of an earlier, smaller survey on the prefinal consultation version of the guideline and confirmed high acceptance rates. Half of the participants were practising neurologists. Neurologists from MS centers with more than 500 patients per year (n=26) were more critical of the guideline. They reiterated some of the criticisms of the previous feedback, and, in particular, felt that safety aspects are overemphasized in the guideline, thereby superseding early aggressive therapy.

U2 - 10.1016/j.msard.2022.103828

DO - 10.1016/j.msard.2022.103828

M3 - Letter

C2 - 35490449

VL - 63

JO - MULT SCLER RELAT DIS

JF - MULT SCLER RELAT DIS

SN - 2211-0348

M1 - 103828

ER -